Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 9/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.41 |
| ▸ | ACP3 | P15309 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8623419 | 0.91 | SLC6A4 (0.46) | SLC6A9SLC6A4ACP3 | |
| SCHEMBL8621492 | 0.87 | ACP3 (0.44) | SLC6A9SLC6A4ACP3MEN1KMT2A | |
| SCHEMBL8620195 | 0.86 | F2 (0.39) | SLC6A9SLC6A4ACP3 | |
| SCHEMBL8622280 | 0.83 | SLC6A2 (0.52) | SLC6A9SLC6A4ACP3MEN1KMT2A | |
| SCHEMBL8626313 | 0.83 | ACP3 (0.39) | SLC6A4ACP3KMT2A | |
| SCHEMBL8619830 | 0.81 | SLC6A2 (0.52) | SLC6A9SLC6A4ACP3MEN1KMT2A | |
| SCHEMBL8620194 | 0.79 | SLC6A4 (0.40) | SLC6A9SLC6A4ACP3 | |
| SCHEMBL8623278 | 0.79 | FDFT1 (0.42) | SLC6A4ACP3 | |
| Sulfuric Acid SCHEMBL143603 | 0.78 | SLC6A4 (0.57) | SLC6A9HTR1ASLC6A4 | |
| SCHEMBL8947061 | 0.78 | SLC6A4 (0.39) | SLC6A9SLC6A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | claimed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | claimed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | claimed |
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | disclosed |
| US-5567841-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |